On March 1, AstraZeneca announced that it had officially signed an investment cooperation agreement for the construction of a new small molecule drug factory in Wuxi with the Management Committee of Wuxi National High-Tech Industrial Development Zone.AstraZeneca to Invest $475 Million in New Small Molecule Drug Factory in Wuxi High-Tech ZoneIt is expected that in the future, specific small molecule drugs of AstraZeneca to be launched in China will be produced from formulation to packaging at the new factory in Wuxi, supplying both domestic and international markets.The new factory will join AstraZeneca's global production and supply base in China, providing high-quality innovative drugs "Made in China" to both domestic and international markets.AstraZeneca's new small-molecule innovative drug facility in Wuxi will be equipped with cutting-edge continuous tablet manufacturing process equipment and sustainable pharmaceutical packaging production lines, establishing an autonomous intelligent manufacturing plant. Upon completion of the new facility, AstraZeneca will further enhance its small-molecule drug production capacity and leverage the company’s agile and efficient global supply network to deliver products to the Chinese and global markets.At the same time, AstraZeneca will continue to play a leading role in the industry, making the new factory a "green and low-carbon model" to promote the high-end, intelligent, and green development of manufacturing in China, and to support the higher-quality and sustainable development of the biopharmaceuticals industry. AstraZeneca has long been committed to achieving the decarbonization goals of its supply chain. From the initial planning stages, the new factory was designed to build a smart factory and zero-carbon factory by increasing the application of green technologies, setting a global example.Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article.For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
